Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the supply of tetrahydrofolate needed for DNA, RNA and protein synthesis. This limits the proliferation of immune cells and malignant cells. Additionally, it increases extracellular adenosine, which has anti‑inflammatory properties that contribute to its effectiveness in rheumatic disorders.

The specific dose of Methofill is individualized by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Healthcare providers determine the appropriate amount, frequency and duration, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Methofill is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because it can cause fetal harm and malformations. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and may affect the infant. Effective contraception is required for both men and women of reproductive potential.

To request Methofill, visit the product page on gnhindia.com and submit an enquiry with the desired quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics if required) and necessary import documentation.

Methofill (methotrexate) is a conventional synthetic DMARD often used before or alongside biologic agents such as TNF‑α inhibitors. Compared with newer biologics, methotrexate is less expensive and administered subcutaneously, but it may require more laboratory monitoring for liver and marrow toxicity. Its efficacy in many patients is comparable, especially when combined with other therapies.

Methofill should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.

Methofill is supplied for subcutaneous injection. A healthcare professional prepares the dose using a sterile syringe and injects it into the subcutaneous tissue, typically in the abdomen or thigh. Patients should be trained on proper injection technique, site rotation and disposal of sharps according to local regulations.

The most critical adverse events to monitor include bone‑marrow suppression leading to severe cytopenias, hepatotoxicity that can progress to fibrosis or cirrhosis, and pulmonary toxicity such as interstitial pneumonitis. Early detection through regular laboratory testing and prompt reporting of respiratory symptoms are essential to mitigate these risks.

Methofill is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic impairment, uncontrolled infections, or known hypersensitivity to methotrexate. Caution is also advised for those with significant renal dysfunction, pre‑existing bone‑marrow disorders, or active pulmonary disease.